Dr Reddy’s Laboratories announced on Saturday that the United States Food and Drug Administration (USFDA) has issued a Form 483 with two observations following an inspection of its API (Active Pharmaceutical Ingredients) manufacturing facility in Middleburgh, New York.In a regulatory filing, the Hyderabad-based pharmaceutical company stated that the GMP (Good Manufacturing Practice) inspection was carried out between May 12 and May 16, 2025, news agency PTI reported.“At the conclusion of the inspection, we received a Form 483 with two observations, which we will address within the stipulated timeline,” the company said.According to the USFDA, a Form 483 is issued when inspectors identify conditions that may potentially violate the Food, Drug, and Cosmetic (FD&C) Act or related regulations. The observations are shared with a firm’s management to prompt corrective action.On May 16, Dr Reddy’s Laboratories Ltd closed at Rs 1,228.50, marking a decline of Rs 7.80 or 0.63% from the previous trading session. Earlier on Friday, Dr Reddy’s Laboratories had reported a 21 per cent year-on-year increase in consolidated net profit to Rs 1,587 crore for the quarter ended March 2025, driven by strong sales across key markets such as the US and India. The Hyderabad-based pharmaceutical company had recorded a net profit of Rs 1,307 crore in the same quarter of the previous year. Revenue for the January–March quarter had risen to Rs 8,506 crore, compared to Rs 7,083 crore a year earlier, according to a regulatory filing. For the full financial year 2024–25, Dr Reddy’s had posted a net profit of Rs 5,724 crore, marking a modest 3 per cent growth over the Rs 5,568 crore reported in FY24. The company’s annual revenue had increased to Rs 32,553 crore from Rs 27,916 crore in the preceding fiscal.India’s Pharma sectorIndia’s pharmaceutical industry, a major supplier to the United States, is likely to come under increasing pressure amid heightened regulatory scrutiny. In FY24, the US accounted for $8.7 billion of India’s total pharma exports of $27.9 billion, according to the Pharmaceuticals Export Promotion Council of India. More than 45% of the generic drugs used in the US are manufactured in India, underscoring the country’s crucial role in the American healthcare system, according to an ET report. Additionally, Indian firms supply approximately 15% of the biosimilars consumed in the US. Leading companies such as Sun Pharma, Dr Reddy’s, Aurobindo Pharma, Zydus Lifesciences, and Gland Pharma generate up to half of their revenues from the US market, making them particularly sensitive to regulatory developments.
